Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

计划入组 48 人 · 首次发布于 2020 年 10 月 14 日

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

计划入组 80 人 · 首次发布于 2020 年 10 月 14 日

Combined AlloStim+Anti-PD-L1 in MSS Metastatic Colorectal Cancer

计划入组 50 人 · 首次发布于 2024 年 8 月 16 日

Ustilago avenae

Avena sativa pollen

Civ1 inhibitors (sanofi-aventis)

Aveni Foundation

United States

Avenzo Therapeutics, Inc.

United States

AVENTIS PHARMA

Egypt

Roche Revolutionizes Genomic Sequencing with Novel Sequencing by Expansion Technology

Foresight Diagnostics and Roche Resolve Patent Dispute with PhasED-Seq Licensing Agreement for Non-Hodgkin's Lymphoma Diagnostics

Avenzo and Gilead Partner to Evaluate Novel Breast Cancer Combination Therapy